Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 3/2021

01-09-2021 | Chronic Lymphocytic Leukemia | review

Chronic lymphocytic leukaemia—what is new and notable in 2021, with a special focus on COVID-19

Authors: Katharina T. Prochazka, Peter Neumeister

Published in: memo - Magazine of European Medical Oncology | Issue 3/2021

Login to get access

Summary

In the last few years, treatment of patients exhibiting chronic lymphocytic leukaemia has changed extensively due to advances in the development of targeted therapies. The role of immunochemotherapy has been for the most part replace and the guidelines have been modified accordingly. Herein, we give an overview on updated onkopedia guidelines, studded with updates of the landmark studies of the latest American Society of Hematology (ASH) meeting. In addition, since still crucial, recommendations concerning coronavirus disease 2019 (COVID-19) in chronic lymphocytic leukaemia patients will be covered.
Literature
1.
2.
Shanafelt T, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–43.CrossRef
3.
Woyach J, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–28.CrossRef
4.
Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–91.CrossRef
5.
Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–36.CrossRef
6.
Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208–15.CrossRef
7.
Eichhorst B, Fink AM, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928–42.CrossRef
8.
Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–10.CrossRef
9.
Allan JN, Shanafelt T, Wiestner A, et al. Long-term efficacy of 1st-line ibrutinib for CLL with 4 years of FU in patients with TP53 aberrations: a pooled analysis from 4 clinical. Blood. 2020;136(Supplement 1):2219.CrossRef
10.
Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107–20.CrossRef
11.
Kater A, Kipps TJ, Eichhorst B, et al. 5‑year analysis of Murano study demonstrates enduring uMRD in a subset of R/R CLL patients following fixed-duration VenR. Blood. 2020;136(Supplement 1):19–21.CrossRef
12.
Hallek M. The broadening landscape of targets and therapeutic options for CLL. In: EBMT handbook. 2021.
13.
Munir T, Brown JR, O’Brien S, et al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94:1353–63.CrossRef
14.
Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (HELIOS): A randomized, double-blind, phase 3 study. Lancet Oncol. 2016;17:200–11.CrossRef
15.
Ghia P, Pluta A, Wach M, et al. ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38:2849–61.CrossRef
16.
17.
Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–92.CrossRef
18.
Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patient. Blood. 2020;135(21):1912–5.CrossRef
19.
20.
Roeker LE, Knorr DA, Pessin MS, et al. Anti-SARS-CoV‑2 antibody response in patients with chronic lymphocytic leukemia. Leukemia. 2020;34:3047–9.CrossRef
21.
Metadata
Title
Chronic lymphocytic leukaemia—what is new and notable in 2021, with a special focus on COVID-19
Authors
Katharina T. Prochazka
Peter Neumeister
Publication date
01-09-2021
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 3/2021
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00735-z

Other articles of this Issue 3/2021

memo - Magazine of European Medical Oncology 3/2021 Go to the issue

case report

Death of unknown cause? Post-mortem diagnosis of fulminant course of an EBV-associated secondary hemophagocytic lymphohistiocytosis

short review

Rehabilitation for children and adolescents after cancer: importance and implementation in Austria

short review

Top 3 abstracts concerning hormone-receptor-positive early breast cancer

editorial

Pediatric oncology 2.0—shaping the future with precision

case report

Sphenoidal mucormycosis associated with large B-cell lymphoma: case report and literature review

short review

Novel agents in a young patient with osteosarcoma: A short review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits